Capitolis Liquid Global Markets LLC Buys 23,812 Shares of Thermo Fisher Scientific Inc. $TMO

Capitolis Liquid Global Markets LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.3% in the 4th quarter, HoldingsChannel reports. The firm owned 121,812 shares of the medical research company’s stock after purchasing an additional 23,812 shares during the quarter. Capitolis Liquid Global Markets LLC’s holdings in Thermo Fisher Scientific were worth $70,584,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. Assetmark Inc. lifted its holdings in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares in the last quarter. Factory Mutual Insurance Co. increased its position in shares of Thermo Fisher Scientific by 2.6% in the third quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock valued at $47,985,000 after acquiring an additional 2,500 shares during the last quarter. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $7,505,000. Finally, ICICI Prudential Asset Management Co Ltd increased its position in shares of Thermo Fisher Scientific by 51.2% in the third quarter. ICICI Prudential Asset Management Co Ltd now owns 17,720 shares of the medical research company’s stock valued at $8,595,000 after acquiring an additional 6,000 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $460.62 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company’s 50 day moving average price is $477.80 and its two-hundred day moving average price is $524.61. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market cap of $171.18 billion, a P/E ratio of 25.32, a P/E/G ratio of 2.09 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.